The Experimental Research of BTJF Medicated Serum Inhibiting on Growth of BXPC-3 Pancreatic Cancer Cell

2018 International Journal of Clinical Chemistry and Laboratory Medicine  
Pancreatic cancer is one of the high degree of malignant tumor, is one of the top ten malignant tumor of causing population death in our country. In recent years, the incidence of pancreatic cancer is gradually rising in worldwide; the mortality Close to morbidity, most patient have belong to middlelate phase after diagnosis ,most patient died in six months [1] [2] [3] [4] .Traditional Chinese medicine is one of replacement therapy in treatment of pancreatic cancer, showing a good application
more » ... good application prospect. I have been using BTJF to treat locally advanced pancreatic cancer, has obtained the good clinical curative effect [5] , and observed in the animal experiments that BTJF can reduce the incidence of HIC1 gene methylation, raised HIC1 gene expression, so as to exert the effect of inhibition on pancreatic cancer cell proliferation [6] .In order to further observe their inhibitory effect on pancreatic cancer cells, I will act BTJF drug-containing serum on BXPC3 human pancreatic cancer cell, we will report the results of the study as follows: Abstract: Objective: To observe the effect of BUQI TONLUO JIEDU FANG (BTJF) medicated serum inhibiting on growth of BXPC-3 pancreatic cancer cell. Methods: BTJF drug-containing serum and control group serum cultivate people BXPC3 pancreatic cancer cell in vitro respectively. By MTT method to, detect OD value of pancreatic cancer cells and the cell proliferation rate in each period, use flow cytometry instrument to detect serum the cell number of G0/G1, S, G2/M phase. Results: Culture to 4h, the cell survival rate was 93.5%, P > 0.05, there was no significant difference in both groups;24h, the cell survival rate was 71.2%, P < 0.05, the OD value in both groups have significant difference;48h, the cell survival rate was 46.9%, P < 0.05, the OD value in both groups have significant difference;72 h, the cell proliferation rate was 19.7%, P < 0.01, the OD value was extremely significant difference in both groups. In S phase, The percentage in drug-containing serum group significantly lower than the blank control group, P < 0.05, the two groups have significant difference, blank control group in G0/G1 phase cell percentage increased significantly, P < 0.05, two groups have significant difference in statistics.G2/M phase, compared two groups, P > 0.05, no significant difference, the PI value in drugcontaining serum group was obviously lower than the control group, P < 0.05, there is significant difference in both group. Conclusion: BTJF medicated serum have significant effect of inhibiting the proliferation of human pancreatic cancer cell.
doi:10.20431/2455-7153.0401001 fatcat:zqrevnjvungs3fn36zsrwrd454